

Effective Date: 8/01/2022
Reviewed: 05/2022, 3/2023, 12/2023, 03/2024, 04/2025, 7/2025, 6/2026
Scope: Medicaid

SKYTROFA (lonapegsomatropin-tcgd)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, and the member has no contraindications or exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Pediatric patients 1 year and older who weigh at least 11.5kg and have growth failure due to inadequate secretion of endogenous growth hormone(GH).
2. Replacement of endogenous growth hormone in adults with growth hormone deficiency(GHD).

All other indications are considered experimental/investigational and not medically necessary.

II. INITIAL CRITERIA FOR APPROVAL

Growth charts are required for pediatric patients with growth hormone (GH) deficiency.

A. **Pediatric GH Deficiency**

Authorization of 12 months may be granted to members with pediatric GH deficiency when the following criteria is met:

1. Therapy must be prescribed by or in consultation with an endocrinologist or pediatric endocrinologist
2. Documentation that the member meets one of the following:
 - a. Member was diagnosed with GH deficiency as a neonate. Medical records must be available to support the diagnosis of neonatal GH deficiency (e.g., hypoglycemia with random GH level, evidence of multiple pituitary hormone deficiency, chart notes, or magnetic resonance imaging [MRI] results).
 - b. Member meets ALL of the following:
 - i. Member has EITHER:
 - a. Two pretreatment pharmacologic provocative GH tests with both results demonstrating a peak GH level < 10 ng/mL, OR
 - b. A documented pituitary or CNS disorder (refer to Appendix A) and a pretreatment IGF-1 level > 2 standard deviations (SD) below the mean
 - ii. For members < 2.5 years of age at initiation of treatment, the pretreatment height is >2 SD below the mean and growth velocity is slow
 - iii. For members ≥ 2.5 years of age at initiation of treatment:
 - a. Pretreatment height is > 2 SD below the mean and 1-year height velocity is > 1 SD below the mean, OR
 - b. Pretreatment 1-year height velocity is > 2 SD below the mean

Effective Date: 8/01/2022
Reviewed: 05/2022, 3/2023, 12/2023, 03/2024, 04/2025, 7/2025, 6/2026
Scope: Medicaid

- iv. Epiphyses are open
- 3. Documentation that member is at least 1 year of age and weighs at least 11.5kg
- 4. Documentation that the member does not have a diagnosis of intracranial tumor growth, psychosocial dwarfism, idiopathic short stature, or history or presence of malignant disease.
- 5. Documentation that the member has had a treatment failure with at least 1 daily growth hormone product (e.g., based on claims review of inadequate adherence or documentation of injection site reactions)

B. Adult GH Deficiency

Authorization of 12 months may be granted to members with documentation of adult GH deficiency prescribed by or in consultation with an endocrinologist and ANY of the following criteria is met:

1. Documentation that the member meets both of the following:
 - i. Member has had 2 pretreatment pharmacologic provocative GH tests and both results demonstrated deficient GH responses defined as the following:
 - a. Insulin tolerance test (ITT) with a peak GH level ≤ 5 ng/mL
 - b. Macrilen with a peak GH level of less than 2.8 ng/mL
 - c. Glucagon stimulation test with a peak GH level ≤ 3.0 ng/mL in patients with a body mass index (BMI) ≤ 30 kg/m² and a high pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI < 25 kg/m²
 - d. Glucagon stimulation test with a peak GH level ≤ 1.0 ng/mL in patients with a BMI of ≥ 25 kg/m² and a low pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI > 30 kg/m²
 - ii. Member has a low pretreatment IGF-1 (between 0 to 2 SD below the mean for age and gender)
2. Documentation that the member meets both of the following:
 - i. Member has had 1 pretreatment pharmacologic provocative GH test that demonstrated deficient GH responses defined as one of the following:
 - a. Insulin tolerance test (ITT) with a peak GH level ≤ 5 ng/mL
 - b. Macrilen with a peak GH level of less than 2.8 ng/mL
 - c. Glucagon stimulation test with a peak GH level ≤ 3.0 ng/mL in patients with a body mass index (BMI) ≤ 30 kg/m² and a high pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI < 25 kg/m²
 - d. Glucagon stimulation test with a peak GH level ≤ 1.0 ng/mL in patients with a BMI of ≥ 25 kg/m² and a low pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI > 30 kg/m²
 - ii. Member has a pretreatment IGF-1 level that is more than 2 SD below the mean for age and gender
4. Documentation that the member meets both of the following:
 - i. Member has organic hypothalamic-pituitary disease (e.g., suprasellar mass with previous surgery and cranial irradiation) with ≥ 3 documented pituitary hormone deficiencies (refer to Appendix B)
 - ii. Member has a low pre-treatment IGF-1 more than 2 standard deviations below the mean for age and gender
5. Documentation that the member has genetic or congenital structural hypothalamic pituitary defects (refer to Appendix C)

Effective Date: 8/01/2022
Reviewed: 05/2022, 3/2023, 12/2023, 03/2024, 04/2025, 7/2025, 6/2026
Scope: Medicaid

6. Documentation that the member has childhood-onset GH deficiency and a congenital abnormality of the CNS, hypothalamus, or pituitary (refer to Appendix C)

III. CONTINUATION OF THERAPY

A. Pediatric GH Deficiency

Authorization of 12 months may be granted for continuation of therapy when ALL of the following criteria are met:

1. Documentation of the member's diagnosis must be provided.
2. Documentation that the member's growth rate is > 2 cm/year unless there is a documented clinical reason for lack of efficacy (e.g., on treatment less than 1 year, hypopituitarism)
3. Documentation that the epiphyses are open (confirmed by X-ray or X-ray is not available)

B. Adult GH Deficiency

Authorization of 12 months may be granted for continuation of therapy for adult growth hormone (GH) deficiency when ANY of the following criteria are met:

1. Documentation that the member meets all of the following:
 - i. Member has had 2 pretreatment pharmacologic provocative GH tests and both results demonstrated deficient GH responses defined as the following:
 - a. Insulin tolerance test (ITT) or another provocative GH test with a peak GH level ≤ 5 ng/mL
 - b. Macrilen with a peak GH level of less than 2.8 ng/mL
 - c. Glucagon stimulation test with a peak GH level ≤ 3.0 ng/mL in patients with a body mass index (BMI) ≤ 30 kg/m² and a high pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI < 25 kg/m²
 - d. Glucagon stimulation test with a peak GH level ≤ 1.0 ng/mL in patients with a BMI of ≥ 25 kg/m² and a low pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI > 30 kg/m²
 - ii. Member has a low pretreatment IGF-1 (between 0 to 2 SD below the mean for age and gender)
 - iii. Current IGF-1 level is not elevated for age and gender
2. Documentation that the member meets all of the following:
 - i. Member has had 1 pretreatment pharmacologic provocative GH test that demonstrated deficient GH responses defined as one of the following:
 - a. Insulin tolerance test (ITT) or another provocative GH test with a peak GH level ≤ 5 ng/mL
 - b. Macrilen with a peak GH level of less than 2.8 ng/mL
 - c. Glucagon stimulation test with a peak GH level ≤ 3.0 ng/mL in patients with a body mass index (BMI) ≤ 30 kg/m² and a high pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI < 25 kg/m²
 - d. Glucagon stimulation test with a peak GH level ≤ 1.0 ng/mL in patients with a BMI of ≥ 25 kg/m² and a low pretest probability of GHD (e.g., acquired structural abnormalities) OR a BMI > 30 kg/m²
 - ii. Member has a pretreatment IGF-1 level that is more than 2 SD below the mean for age and gender
 - iii. Current IGF-1 level is not elevated for age and gender
3. Documentation that the member meets both of the following:

Effective Date: 8/01/2022
Reviewed: 05/2022, 3/2023, 12/2023, 03/2024, 04/2025, 7/2025, 6/2026
Scope: Medicaid

- i. Member has organic hypothalamic-pituitary disease (e.g., suprasellar mass with previous surgery and cranial irradiation) with ≥ 3 documented pituitary hormone deficiencies (refer to Appendix B) and a low pretreatment IGF-1 more than 2 standard deviations below the mean for age and gender
 - ii. Current IGF-1 level is not elevated for age and gender
4. Documentation that the member has genetic or structural hypothalamic-pituitary defects (refer to Appendix C) and current IGF-1 level is not elevated for age and gender
5. Documentation that the member has childhood-onset GH deficiency and a congenital abnormality of the CNS, hypothalamus or pituitary (refer to Appendix C) and current IGF-1 level is not elevated for age and gender

IV. APPENDICES

A. Appendix A: Examples of Hypothalamic/Pituitary/CNS Disorders

1. Congenital genetic abnormalities
 - a. Known mutations in growth-hormone-releasing hormone (GHRH) receptor, GH gene, GH receptor, or pituitary transcription factors
 - b. Perinatal insults
2. Congenital structural abnormalities
 - a. Optic nerve hypoplasia/septo-optic dysplasia
 - b. Agenesis of corpus callosum
 - c. Empty sella syndrome
 - d. Ectopic posterior pituitary
 - e. Pituitary aplasia/hypoplasia
 - f. Pituitary stalk defect
 - g. Anencephaly or prosencephaly
 - h. Other mid-line defects
 - i. Vascular malformations
3. Acquired structural abnormalities (or causes of hypothalamic/pituitary damage)
 - a. CNS tumors/neoplasms (e.g., craniopharyngioma, glioma, pituitary adenoma)
 - b. Cysts (Rathke cleft cyst or arachnoid cleft cyst)
 - c. Surgery
 - d. Radiation
 - e. Chemotherapy
 - f. CNS infections
 - g. CNS infarction (e.g., Sheehan's syndrome)
 - h. Inflammatory lesions (e.g., autoimmune hypophysitis)
 - i. Infiltrative lesions (e.g., sarcoidosis, histiocytosis)
 - j. Head trauma/traumatic brain injury
 - k. Aneurysmal subarachnoid hemorrhage

B. Appendix B: Pituitary Hormones (Other than Growth Hormone)

1. Adrenocorticotrophic hormone (ACTH)
2. Antidiuretic hormone (ADH)
3. Follicle stimulating hormone (FSH)

Effective Date: 8/01/2022
Reviewed: 05/2022, 3/2023, 12/2023, 03/2024, 04/2025, 7/2025, 6/2026
Scope: Medicaid

4. Luteinizing hormone (LH)
5. Thyroid stimulating hormone (TSH)
6. Prolactin

C. Appendix C: Requirements for GH-Stimulation Testing in Adults

1. Testing for adult GHD is not required
 - a. Three or more pituitary hormone deficiencies and low IGF-1
 - b. Congenital structural abnormalities
 - i. Transcription factor defects (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2)
 - ii. GHRH receptor-gene defects
 - iii. GH-receptor/post-receptor defects
 - iv. GH-gene defects associated with brain structural defects
 - v. Single central incisor
 - vi. Cleft lip/palate
 - c. Acquired causes such as perinatal insults
2. Testing for adult GHD is required
 - a. Acquired
 - i. Skull-base lesions
 - ii. Pituitary adenoma
 - iii. Craniopharyngioma
 - iv. Rathke's cleft cyst
 - v. Meningioma
 - vi. Glioma/astrocytoma
 - vii. Neoplastic sellar and parasellar lesions
 - viii. Chordoma
 - ix. Hamartoma
 - x. Lymphoma
 - xi. Metastases
 - xii. Other brain injury
 - xiii. Traumatic brain injury
 - xiv. Sports-related head trauma
 - xv. Blast injury
 - xvi. Infiltrative/granulomatous disease
 - xvii. Langerhans cell histiocytosis
 - xviii. Autoimmune hypophysitis (primary or secondary)
 - xix. Sarcoidosis
 - xx. Tuberculosis
 - xxi. Amyloidosis
 - b. Surgery to the sella, suprasellar, and parasellar region
 - c. Cranial irradiation
 - d. Central nervous system infections (bacteria, viruses, fungi, parasites)
 - e. Infarction/hemorrhage (e.g., apoplexy, Sheehan's syndrome, subarachnoid hemorrhage, ischemic stroke, snake bite)
 - f. Empty sella
 - g. Hydrocephalus
 - h. Idiopathic

Effective Date: 8/01/2022
Reviewed: 05/2022, 3/2023, 12/2023, 03/2024, 04/2025, 7/2025, 6/2026
Scope: Medicaid

V. REFERENCES

1. Skytrofa [package insert]. Palo Alto, CA: Ascendis Pharma, Inc.; September 2025. Accessed May 2026.
2. American Association of Clinical Endocrinologists Growth Hormone Task Force. Medical guidelines for clinical practice for growth hormone use in adults and children 2003 Update. *Endocr Pract.* 2003;9(1):64-76.
3. National Institute for Clinical Excellence: Guidance on the use of human growth hormone (somatropin) for the treatment of growth failure in children. May 2010.
<http://www.nice.org.uk/nicemedia/live/12992/48715/48715.pdf>. Accessed January 28, 2019.
4. Wilson TA, Rose SR, Cohen P, et al. Update of Guidelines for the Use of Growth Hormone in Children: The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. *J Pediatr.* 2003;143:415-421.
5. Franklin SL, Geffner ME. Growth hormone: the expansion of available products and indications. *Pediatr Clin North Am.* 2011;58:1141-1165.
6. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. *Horm Res Paediatr.* 2016;86:361-397.